6.21-7.4 期间，医药生物板块涨幅为2.76%，在所有板块中位列第七位，跑赢沪深300 指数2.96 个百分点；年初至今，医药生物板块涨幅为10.71%，跑赢沪深300 指数11.41 个百分点。从子板块看，6.21-7.4 期间，中药和医疗服务涨跌幅分别为11.18%和4.20%，跑赢整体板块；医疗器械、生物制品、医药商业和化学制药涨跌幅分别为2.72%、2.43%、 -0.51%和-1.61%，跑输整体板块。从年初来看，医疗服务、中药和医疗器械涨跌幅分别为30.14%、25.85%和14.61%，跑赢整体板块；
生物制品、化学制药和医药商业涨跌幅分别为7.96%和-3.93%和-13.75%，跑输整体板块。

1．行情回顾 ........................................................................................................................................... 4
1.1 医药生物行情回顾 ····················································································································· 4
1.2 医药生物子板块行情回顾 ········································································································· 5
1.3 医药生物板块估值 ····················································································································· 6
1.4 医药生物板块个股表现 ············································································································· 7
2．行业要闻 ........................................................................................................................................... 8
3．投资建议 ........................................................................................................................................... 9
4．风险提示 ......................................................................................................................................... 10